Department of Pathology and Laboratory Medicine, Department of Pediatrics, Broad Stem Cell Research Center, University of California Los Angeles (UCLA), David Geffen School of Medicine, 610 Charles E Young Drive East, Los Angeles, CA 90095-1732, USA.
Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):331-41. doi: 10.1016/j.addr.2010.12.006. Epub 2011 Jan 11.
The concept that stem cells can be used to replace and regenerate tissue was founded over half a century ago using hematopoietic stem cells in the clinical field of bone marrow transplantation. The development of human embryonic stem cell lines and patient-specific induced pluripotent stem cells has the potential to overcome the problem presented by shortages of immunologically compatible hematopoietic stem cell donors. This review summarizes the current advances made and limitations to be overcome in order to realize the full potential of engineering blood from pluripotent stem cells for clinical use.
半个多世纪以前，人们就已经通过在骨髓移植的临床领域中使用造血干细胞，奠定了干细胞可以用于替代和再生组织的概念基础。人胚胎干细胞系和患者特异性诱导多能干细胞的发展，有可能克服由于免疫相容的造血干细胞供体短缺而带来的问题。这篇综述总结了目前已经取得的进展和需要克服的限制，以便充分发挥多能干细胞生成血液用于临床应用的潜力。
